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Summary
Background—Two strategies for prevention of upper gastrointestinal (UGI) events for non-
selective (ns)NSAID users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective
inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA).
Aim—To identify whether and in whom either of these strategies should be preferred in daily
practice.
Methods—A nested case-control study was conducted using three European primary care
databases. We selected a cohort including all naive nsNSAID+GPA (≥ 80% GPA adherence) and
coxib users (without GPA use) aged ≥50 years. Cases with an UGI event (i.e. symptomatic UGI
ulcer or bleeding (UGIB) were matched to cohort members without an UGI event on age, sex and
number of individual UGI risk factors (i.e. UGI event history, age≥65 years, concomitant use of
anticoagulants, antiplatelets, or glucocorticoids) and calendar time. Conditional logistic regression
analysis was used to calculate odds ratios (ORs) with 95% confidence intervals (CI), while
adjusting for potential confounders.
Results—Within the NSAID cohort (n=617,220), 398 UGI cases were identified. The risk of
UGI events was equivalent for coxib and nsNSAID+GPA (≥80% adherence) users (OR: 1.02;
95%CI:0.77-1.37). In concurrent glucocorticoid users, the risk of UGI events was significantly
elevated for nsNSAID+GPA (≥80% adherence) compared to coxib users (OR: 9.01; 95%CI:
1.61-50.50).
Conclusions—The risk of UGI events was similar in nsNSAID+GPA (≥80% adherence) and
coxibs users. In patients concurrently using glucocorticoids a significant increase in the risk of
UGI events for nsNSAID+GPA users was observed and coxibs should be preferred.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed by both general
practitioners and medical specialists, and serve as key pharmacological agents in the
management of arthralgic and inflammatory conditions. Multiple epidemiologic studies and
prospective clinical outcome trials have characterized the risk of NSAID-related
gastrointestinal (GI) complications, which include upper gastrointestinal (UGI) ulcers and
bleeding. To mitigate the increased risk among long term NSAID users, guidelines have
been developed and strategies are recommended 1-4 including prescription of cyclo-
oxygenase (COX)-2-selective inhibitors (coxibs) or concurrent use of gastroprotective
agents (GPAs), such as proton pump inhibitors (PPIs). Although both preventive strategies
aim to reduce the incidence of UGI events, the risk of such complications is not eliminated;
a considerable proportion of NSAID plus GPA users (6.3-8.5%) and coxib users (3.7-8.9%)
continues to experience UGI events. 5-8 Defining which of the two preventive strategies is
preferred in terms of UGI safety has been the scope of recent studies. Most of the
randomized clinical trials showed no superiority for one of the preventive strategies over the
other. 5-7, 9 Only one large randomized clinical trial showed a beneficial effect in favor of
celecoxib. In this 6 month trial patients randomized to celecoxib, as compared to the
combination of diclofenac and omeprazole, had a reduced rate of clinically significant
overall gastrointestinal events when a composite endpoint was considered (events from both
the upper and lower GI tract). Looking at the upper gastrointestinal tract specifically, this
head to head comparison demonstrated similar rates for upper gastrointestinal bleeding. 10
Extrapolation of the previously described body of literature to guide clinicians in the care of
the general population has several limitations. Many of the prospective randomized clinical
studies have included patients using supra-therapeutic doses of coxibs or included a selected
group of high-risk patients (i.e. those with a recent UGI event).5-7, 10 Alternatively in some
of the prospective trials, the presence of co-morbid diseases such as ischemic heart disease,
peripheral arterial disease 10, or congestive heart failure 5 were considered as exclusion
criterion, thereby preferentially selecting patients at lower risk of UGI events. Additionally,
the exclusion of patients with frequently used co-medication (e.g. low-dose aspirin 5,
anticoagulant agents 5, 7 and corticosteroids 7) in some of the studies might be an important
issue, considering that the use of low-dose aspirin clearly influences the efficacy of UGI
protection in coxibs. 11-12 Finally, as a consequence of protocol driven inclusion of patients
with recent or past UGI bleeding and in some studies, the recruitment of patients from
hospital-setting 5, 10 or endoscopy centers 6-7, a substantial number of enrolled subjects may
have had NSAID-associated complications and as such a higher risk.
Apart from the clinical studies, one population-based cohort study concluded that coxibs
alone were not superior to nsNSAID combined with PPI in the prevention of hospitalization
for a perforated or bleeding ulcer.13 This observation was confirmed in an observational
case-control study, using a population-based claims-database in Canada, in which both
gastroprotective strategies were similarly effective in the prevention of NSAID-related UGI
events, but it did not address the lack of adherence to PPIs.14 However, we and others have
demonstrated that in real life, GPA adherence during nsNSAID use is an important factor to
consider when evaluating and comparing the effectiveness of different gastroprotective
strategies. If the NSAID and PPI are given as separate medications non- or low adherence to
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GPAs is often seen15 and associated with significantly increased risk of nsNSAID-related
upper GI events. 16-18
Thus, whether coxibs and nsNSAIDs plus GPA are similarly effective in preventing incident
NSAID-related UGI events in daily clinical practice including patients both at high- and
low-risk is still unknown. Therefore, we conducted a case-control study to compare the risk
of UGI events between coxib users and nsNSAID users, who were highly GPA adherent (at
least 80% adherence to GPAs), making use of population-based primary health care data
from three European countries. As coxibs might be preferentially prescribed to specific
patient groups, we restricted to nsNSAID users who were highly GPA adherent (at least
80% adherence to GPAs).
Materials and Methods
Description of data sources
Three similar European population-based primary care registries served as data sources:
1)the General Practice Research Database (GPRD) from the United Kingdom (UK, 1998–
2008), 2)the Integrated Primary Care Information database (IPCI) from the Netherlands
(1996–2007), and 3)the Health Search/CSD Longitudinal Patient Database (HSD) from Italy
(2000–2007). In these three countries, all citizens are registered with a primary care practice,
who acts as a gatekeeper to secondary and tertiary medical care. For each individual patient
all relevant medical information from primary and secondary care, as well as additional
information, including demographics and drug prescriptions, is recorded in the health care
medical record. All three registries comply with European Union guidelines on the use of
medical data for research. The protocol of the present study was approved by the Medical
Ethics Committee of each database. We have previously shown the validity to combine and
to compare data from these databases. 17, 19 For GPRD, the READ dictionary was used to
identify medical diagnosis and symptoms, whereas the International Classification for
Primary Care 20 and the International Classification of Diseases, 9th Revision, Clinical
Modification (ICD-9-CM) 2121 were used for that purpose in IPCI and HSD, respectively. In
IPCI and HSD information on drug prescription was coded according to the Anatomical
Therapeutical Chemical (ATC) classification. 2222 In GPRD information on drugs is
captured with MULTILEX product dictionary and British National Formulary (BNF) codes.
Determination of NSAID cohort
The identification of the source population and NSAID cohort has been described
elsewhere.17 In brief, a source population was identified within each database by inclusion
of patients from start of the study period, 50 years of age or the date that one year of valid
data within the database was available, whichever was the most recent. The one-year period
prior to inclusion in the source population was required for valid assessment of baseline
characteristics and inclusion and exclusion criteria at the time of NSAID prescription. A
cohort of patients who newly started (i.e. no NSAID prescriptions within 6 months prior to
inclusion) on either coxibs or nsNSAIDs (excluding the fixed combination of diclofenac
with misoprostol) was identified. Exclusion criteria were history of gastrointestinal tract
cancer, alcohol abuse, chronic liver disease, inflammatory bowel disease, or coagulopathy.
Within the cohort of new users, all episodes of NSAID use were determined and defined as
consecutive NSAID prescriptions with intervening gaps not exceeding the duration of the
previous NSAID prescription(Figure 1). The duration of an NSAID episode was calculated
by dividing the prescribed quantity by daily dose regimen (GPRD/IPCI) or the indication-
specific defined daily dose (HSD). The end of an NSAID episode was defined as the end of
the duration of the last NSAID prescription within that episode or the end of follow-up,
whichever was earliest. All episodes from a patient were eligible for inclusion if the
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previous NSAID-prescription ended at least 6 months before the start of the next episode.
The density of NSAID use was calculated by the number of NSAID prescription days
divided by episode length. Eligible gastroprotective agents (GPAs) were proton pump
inhibitors (PPIs), double-dosed histamine2 receptor antagonists (H2RAs), and misoprostol.
For the present study, non-selective NSAID users were excluded if they did not use a GPA
concomitantly, or if they were non-adherent to the concomitantly used GPA (i.e. coverage of
less than 80% of the nsNSAID days). In total, 68.1% of NSAID plus GPA users were highly
adherent. 17 The exposure assessment and GPA adherence calculation are schematically
depicted in Figure 1. The GPA adherence calculation has been described previously.18
NSAID episodes during which patients switched between classes of NSAIDs (from
nsNSAID to coxib or vice versa) were excluded. Episodes during which coxibs were used
concurrently with a GPA were also excluded. Overall, in 83.4% of coxib episodes no GPA
was used concomitantly. 19 This resulted in a cohort including only nsNSAID plus GPA
(≥80 % adherence) and coxib (alone) users.
Cases and controls selection
Outcomes of interest were a composite of UGI events (including symptomatic ulceration,
UGI bleeding (UGIB), perforation or obstruction) and UGIB alone. Identification of the
outcomes has been described in more detail elsewhere. 17 The date of outcome (i.e. index
date) was determined as date of start of symptoms leading to the diagnosis of the UGI event,
or if this date was unknown, date of diagnosis. Events occurring within 60 days after the end
of an NSAID episode were attributed to the previous NSAID use.23
A nested case-control study was conducted. To each case experiencing an UGI event during
or within 60 days after the end of an NSAID episode, we matched all control persons from
the cohort of the corresponding database. Controls had not experienced any UGI event at the
index date of the corresponding case and were at the index date alive, using an NSAID
within 60 days prior, had equal number of UGI risk factors (see below) as the case and had
similar age (±3 years) and same gender.
Covariates
We considered as risk factors for UGI events those that are commonly reported in literature:
(i) age ≥ 65 years; (ii) a history of UGI events (bleeding/ulceration); (iii) concurrent use of
anticoagulants; (iv) concomitant use of antiplatelets (including aspirin ≤ 325 mg/day); and
(v) concomitant use of glucocorticoids (equipotent dose of ≥5 mg prednisone). Presence of
risk factors was determined by electronic searches in all available data prior to or noted at
the index date.
Additional potential confounding factors were assessed: dyspepsia in the year before the
NSAID episode, (history of) smoking, presence of heart failure or diabetes mellitus, and
concomitant use of drugs associated with increased risk of bleeding (selective serotonin
reuptake inhibitors (SSRI), spironolactone or calcium antagonists) at the index date.
Statistical analyses
Baseline characteristics of cases and controls were described by database and compared
using univariate conditional logistic regression analyses.
To estimate the risk for UGI events and UGI bleeding among nsNSAID + GPA users(≥80%
adherence) in comparison to coxib users, matched and adjusted odds ratios (OR) with 95%
confidence intervals (CIs) were calculated using conditional logistic regression analyses for
each database separately and as pooled analysis. The odds ratio can be interpreted as an
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estimate of the relative risk, as person-time is inherently accounted for in the analysis and
the underlying source population is representative of the general population.24 The pooling
of data across databases was performed by two methods: 1) on patient-level (respecting
matched cases and controls from the original database); and 2) on study-level by estimating
the risk of UGI events for nsNSAID + GPA(≥80% adherence) use versus coxib use per
database and pooling the three obtained risk estimates using a meta-analytic approach,
resulting in an overall risk estimate (inverse variance model) using a random-effects model.
The latter method is only appropriate when there is no heterogeneity.
Identification of confounders was performed by entering each potential confounder into the
model one by one and were kept in the final model if the risk estimate for the drug exposure
changed by more than 10%. As the duration coxibs use might differ from use of nsNSAIDs
+GPA (≥80% adherence) we adjusted also for duration of the episodes and density of
NSAID use. Subsequent analyses evaluated the risk of UGI events and UGI bleeding
stratified by the presence of individual risk factors: age ≥65 years, history of UGI event, and
use of concomitant medications (antiplatelets, anticoagulants and glucocorticoids). For
glucocorticoids, we considered an equipotent dose of prednisone 5 to 10 mg/day as low-
dosage; > 10 to 20 mg/day as moderate dosage and >20 mg/day as high-dosage.
Multiplicative interaction was tested to identify effect modification by all of the individual
UGI risk factors.
All analyses were performed using SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill).
Statistical significance was defined as a two-sided p-value<0.05.
Results
Patient characteristics
We identified 384,469 new NSAID users in the United Kingdom (UK), 307 of who
experienced an UGI event (194 with UGI bleeding). In the Netherlands 17 cases with an
UGI event (14 with UGI bleeding) were identified from 55,004 new users of NSAIDs and in
Italy 74 cases with an UGI event (17 with UGI bleeding) were identified from 177,747 new
NSAID users. Overall, 57,568 event-free controls were matched to these 398 UGI event
cases. Median number of controls was 120 per case (interquartile range: 43-201).
Baseline characteristics of the cases and matched controls are shown in Table 1. In the UK,
the most commonly prescribed nsNSAID was ibuprofen (56%), while celecoxib and
rofecoxib were the most commonly prescribed coxibs (48% and 40%, respectively). In NL,
the most commonly prescribed coxib and nsNSAID were rofecoxib (58%) and diclofenac
(52%), respectively. Diclofenac and nimesulide accounted for the greater part of nsNSAIDs
in Italy (22% and 25%, respectively), whereas celecoxib (51%) and rofecoxib (41%) were
the most frequently prescribed coxibs. Proton pump inhibitors comprised the majority of co-
prescribed GPAs in nsNSAID users across countries (UK:99.6%, NL:97.0%, IT:95.8%).
In the UK, UGI event cases reported more often a history of UGI event (OR: 1.50; 95% CI:
1.04-2.16) and used concomitant anticoagulant therapy (OR: 1.85; 95% CI: 1.06-3.25) and
SSRIs more frequently (OR: 1.92; 95% CI: 1.33-2.77). In the Netherlands and Italy, UGI
event cases were significantly more likely to receive concomitant antiplatelet therapy in
comparison to controls (ORNL: 6.91; 95% CI: 1.07-44.57, and ORIT: 3.12; 95% CI:
1.36-7.17). UGI bleeding cases in UK were more likely to receive concomitant
anticoagulants (OR: 2.56; 95% CI: 1.38-4.75), whereas no significant differences in
anticoagulant use were observed between UGIB cases and controls in the Netherlands and
Italy. From all UGI event cases in the UK, the Netherlands and Italy, respectively 11.7%,
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11.8% and 32.4% had no documented UGI risk factor. The majority of cases were identified
as having one or two documented UGI risk factors.
Across all three countries, most NSAID episodes were of short duration (i.e. less than 1
month), ranging from 53% in the UK to 85% in IT. The proportion of patients treated for 1-6
months ranged from 14% in IT to 29% in UK, while 0.9% to 19% of patients in the three
countries were treated for more than 6 months. The median duration of coxib episodes was
30 days (interquartile range: 20-91 days) and median duration of nsNSAID +GPA (≥80%
adherence) episodes was 28 days (interquartile range: 14-79 days).
Risk of UGI events and UGI bleeding
To compare the risk of UGI event between use of coxibs alone versus highly adherent
nsNSAID+GPA use, a nested case-control study was conducted. From the adjusted model,
no statistically significant decreased or increased risk was observed for nsNSAID + GPA
users (≥80% adherence) as compared to coxib users (Table 2). This holds true for the three
countries separately and as pooled estimates on patient level (Table 2). Regarding UGIB
specifically, similar results were observed. For both outcomes, a trend towards a more
protective effect for nsNSAID+GPA (≥80% adherence) as compared to coxibs was observed
in the Netherlands and Italy (Table 2), but the adjusted model did not show a significant
benefit (Table 2).
Meta-analysis of studies conducted at individual database-level using a random effects
model (no significant heterogeneity between databases was shown, I-squared values of 0%)
did not report different results from pooling on patient-level. Using this meta-analytic
approach, adjusted ORs for UGI events and UGI bleeding following nsNSAID+GPA (≥80%
adherence) compared to coxib use were 1.00 (95% CI: 0.73-1.33) and 1.11 (95% CI:
0.76-1.63), respectively.
Subgroup analyses
Stratification according to the predefined individual UGI risk factors was performed to
identify a possible preference for either strategy in specific risk groups (Table 3). Since most
cases of UGI events occurred in subjects aged 75 years and older, we performed additional
analyses taking a different cut-off age of 75 years, which did not demonstrate different
estimates from the cut-off of 65 years (data not shown). In non-antiplatelet users a non-
significant increased risk both for UGI events and UGI bleeding was observed for nsNSAID
+GPA (≥80% adherence), whereas the opposite was found for antiplatelet users. This
interaction term was significant.
When we compared coxib use with highly adherent nsNSAID+GPA use in glucocorticoid
users, the use of nsNSAID+GPA increased the risk for UGI events considerably (OR: 7.03;
95% CI 1.35-36.45)(P=0.020). When adjusting for the dosage of glucocorticoids, the
estimated risk increased even more (OR: 9.01; 95% CI: 1.61-50.50)(P=0.012). Higher
dosage of glucocorticoids affected the risk of UGI events more as a dose-response
relationship was observed (data not shown). Regarding multiplicative interaction, the
interaction term for use of glucocorticoids was not significant.
The withdrawal of rofecoxib from the market in 2004 influenced in general the prescription
pattern of NSAIDs. After 2004 only celecoxib, etoricoxib, valdecoxib and parecoxib were
available in Europe. Therefore, stratification according to time period was performed. A
decrease in percentage of cases and controls using a coxib was noticed after rofecoxib was
not available on the market anymore. However, this did not impact on the risk of an UGI
event for nsNSAIDs+GPA versus coxibs (Table 3).
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Discussion
In this case-control study we demonstrate that the risk of an UGI event or UGI bleeding is
not different between users of non-selective (ns)NSAIDs in combination with adherent use
of a gastroprotective agent (GPA) and coxib users.
Lowering the risk of NSAID-related UGI events can be achieved by concomitant use of
GPAs. In particular increasing adherence to GPAs is important in reducing the risk
nsNSAID-related UGI events.16-18 As another preventive strategy, COX-2- selective
inhibitors were developed to improve the gastrointestinal safety of NSAID therapy,
especially in high-risk patients such as elderly (aged ≥65 years) patients, those with a history
of UGI events or concomitantly using anticoagulants, antiplatelets or corticosteroids. After
the introduction of coxibs, it was shown that they indeed were associated with less
gastrointestinal toxicity as compared to the traditional non-selective NSAIDs alone. 11, 25-27
Several studies on this topic have been published in recent years.28 Though the
implementation of preventive strategies has increased in recent years, there is still room for
considerable improvement with regard to use of preventive strategies during NSAID
therapy.16, 29 In order to investigate which preventive strategy is superior with regard to
UGI safety, head-to-head comparisons between coxibs and NSAIDs combined with GPAs
have been performed in randomized studies. These studies showed no preference of one
strategy over the other.5-7, 9-10 However, most clinical studies do not allow generalization of
their results to daily clinical practice in Western countries, since many studies included
selected categories of patients (i.e. high-risk patients with endoscopically documented UGI
bleed/ulcer- or with specific disease, in particular rheumatoid arthritis), were performed in
non-Caucasian persons, and in persons at very high risk of an UGI event.
Our results are in keeping with another observational study by Targownik et al. showing no
superiority of nsNSAID combined with PPI use to coxibs in the prevention of NSAID-
related UGI events.14 Although the efficacy of both preventive strategies overall seems
equivalent for the upper gastrointestinal tract in the CONDOR study, the coxib-treated
patients appeared to have a reduced risk of lower GI events as compared to nsNSAID plus
PPI use. 10, 30 However, results from other studies evaluating lower GI tract events as an
outcome were conflicting. 31-34 A post hoc analysis of a prospective study showed a lower
rate of serious lower GI events for rofecoxib compared to naproxen30, whereas this was not
confirmed in a cross-sectional capsule enteroscopy study showing comparable small-bowel
damage between long-term NSAID and coxib users.34 Mechanistically, whether the impact
of NSAIDs on lower GI events reflect a reduction in risk by coxib-use or an increase in risk
by PPI-use due to altered intestinal bacteria and increased susceptibility to small intestinal
bacterial overgrowth is still under debate.35 Another area of potential benefit of coxibs over
nsNSAID plus GPA use might be in selected high-risk groups. In this study, we found that
in glucocorticoid users, adherent use of an nsNSAID plus GPA was associated with a nine
times higher UGI event risk compared to coxibs. This finding is supported by the dose-
response relationship we observed where a higher dosage of glucocorticoids affected the risk
of UGI events more than a lower dosage. The interaction term was not significant, but this is
due to limited power since the estimates differed largely. To our knowledge, no previous
study studied the comparison of coxib and nsNSAID plus GPA use in glucocorticoid users
separately. Although data on glucocorticoids as an independent risk factor for UGI events
are scarce, prior studies have shown a two-fold increased risk of UGI bleeding during
glucocorticoid use alone. 36-39 When glucocorticoids are used in combination with NSAIDs,
the risk of UGI bleeding is estimated higher as compared to NSAID use alone or
glucocorticoid use alone.36-39 Up to now, the reason for the interaction between both drugs
has not been elucidated. One might speculate that glucocorticoids and NSAIDs act
synergistically; experimental studies have shown that glucocorticoids inhibit the healing of
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gastric mucosal damage 40-41 as well as NSAIDs do, although the mechanism of inhibition
differs. Alternatively, gastric bacterial overgrowth due to acid-suppression such as occurs by
PPI use 42-43 might aggravate gastric mucosal damage by increased exposure time of gastric
flora to the mucosal surface or by delayed gastric emptying caused by PPIs. 44 The
combination of nsNSAIDs and PPIs therefore may have led to the observed increased risk in
concurrent glucocorticoid users. As use of steroids is a risk factor that according to
guidelines often will initiate GPA in NSAID-treated patients, this aspect is important to
investigate in future studies.
Although not significant, we found a tendency towards an increased UGI event risk in
patients with a history of an UGI event among nsNSAID plus adherent GPA users as
compared to coxib users. In this particular high-risk patient group, one might consider the
addition of a GPA to a coxib. This combination has been shown to reduce the risk of
NSAID-related UGI events to a higher degree than coxibs alone or nsNSAIDs plus PPIs. 14
In line with previous studies, concomitant use of low-dose aspirin seems to eliminate the
UGI risk benefit of coxibs. 12, 26-27, 45 Though not significant, we observed an increased
UGI risk among nsNSAID plus adherent GPA compared to coxib users who did not
concomitantly use aspirin, whereas the opposite was true for concomitant aspirin users. The
interaction term was significant, pointing to an increase in risk of UGI events for coxibs
when aspirin is used concurrently. In patients concomitantly using antiplatelets (including
low-dose aspirin), GPAs should be recommended not only to nsNSAIDs users, but perhaps
also to coxib users.3, 14, 19 The strength of the current study is the scale and setting: primary
health care data from three European countries were combined reflecting real-life
prescription patterns. Due to the setting it was possible to study both low-risk as well as
high-risk patients. Previous evidence from clinical trials focused generally on high risk
patients only. 5-7
The following limitations should be acknowledged. By performing observational studies,
certain biases can be introduced of which confounding-by-indication is the most important
one to discuss. Confounding-by-indication could have been introduced as the general
practitioner’s awareness of the UGI risk profile of the individual patient might have
influenced the prescribed preventive strategy. After the introduction of coxibs, high-risk
patients were more likely to receive a coxib instead of co-prescription of a GPA to
NSAIDs. 46 Nevertheless, the preference for preventive strategies changed after warnings
for an increased cardiovascular risk related to coxibs were released by regulatory agencies.47
Although the risk of UGI complications with rofecoxib used to be higher than with
celecoxib48, in a stratified analysis the estimate of nsNSAIDs plus GPAs compared to
coxibs without rofecoxib after 2004 (i.e. celecoxib, etoricoxib, valdecoxib and lumiracoxib
only) did not differ from the estimate including rofecoxib (before withdrawal). It is therefore
unlikely that data on the use of rofecoxib prior to its withdrawal would have skewed the GI
safety data in favor of the nsNSAID. We feel that it is therefore unlikely that the channeling
away from coxibs for patients with cardiovascular disease would have led to important
confounding.
We tried to address confounding-by-indication by matching on the number of UGI risk
factors and by restricting the comparator group to nsNSAID users who were highly adherent
to GPA (defined as at least 80% of nsNSAID days covered by a GPA prescription).
Although crude incidence rates appeared to be equal between different levels of GPA
adherence17, from previous studies we know that patients being adherent to the prescribed
GPA are at the highest risk of nsNSAID related UGI events. 17-18 Residual confounding due
to exclusion of users with a lower GPA adherence level is therefore unlikely. In addition, we
selected patient groups with a similar UGI risk profile, by matching on number of UGI risk
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factors, as well as gender and age. Comparison between coxib and nsNSAID plus highly
adherent GPA users showed no differences in number of UGI risk factors. Confounding was
also dealt with by adjusting for several co-morbid conditions. The indication of
glucocorticoid use could only be identified in the Netherlands, of which 64% was for
rheumatoid disorders. Nevertheless, residual confounding cannot be ruled out in
observational studies.
In addition, over-the-counter use of nsNSAIDs and GPA is not recorded in the databases and
could have led to a potential underestimation of its use. We used drug prescription data
rather than precise information on the actual use. Furthermore, the method of GPA
adherence calculation used in the present study determined adherence based on days of GPA
and of nsNSAID use, rather than daily coverage. However, we selected a group of highly
adherent nsNSAID plus GPA users based on a cut off of 80% of GPA adherence.
In conclusion, there is no difference in the risk of UGI events between the use of coxibs and
use of nsNSAIDs plus adherent GPA in daily clinical practice. Neither strategy was superior
in the prevention of a first or a recurrent UGI event or UGI bleeding. A significant increase
in the risk of UGI events for coxibs was observed when aspirin is used concurrently,
whereas during concomitant glucocorticoid use nsNSAID plus GPA users are at increased
risk of an UGI event compared to coxib users. Future studies on this topic are needed, as use
of steroids is a risk factor that, according to guidelines, often will initiate GPA therapy in
NSAID-treated patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Footnotes
Correspondence to: Gwen MC Masclee, M.D. Dept. of Medical Informatics Erasmus University Medical Center
PO Box 2040 3000 CA Rotterdam The Netherlands Phone: +31 10 7044116 Fax: +31 10 7044722
g.masclee@erasmusmc.nl
Guarantor of the article: Gwen MC Masclee
Author Contributions: Gwen MC Masclee: acquisition of data; analysis and interpretation of data; drafting of the
manuscript; statistical analysis
Vera E Valkhoff: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the
manuscript; statistical analysis.
Eva M van Soest: study concept and design; acquisition of data; drafting of the manuscript; critical revision of the
manuscript for important intellectual content; study supervision.
Giampiero Mazzaglia: acquisition of data; critical revision of the manuscript for important intellectual content
Mariam Molokhia: acquisition of data; critical revision of the manuscript for important intellectual content
René Schade: acquisition of data; critical revision of the manuscript for important intellectual content
Gianluca Trifirò: acquisition of data; critical revision of the manuscript for important intellectual content
Jay L Goldstein: acquisition of data; critical revision of the manuscript for important intellectual content
Sonia Hernández-Dí az: acquisition of data; critical revision of the manuscript for important intellectual content
Ernst J Kuipers: analysis and interpretation of data; critical revision of the manuscript for important intellectual
content
Miriam C J M Sturkenboom: study concept and design; acquisition of data; analysis and interpretation of data;
critical revision of the manuscript for important intellectual content; obtained funding; study supervision
All authors approved the final version of the manuscript.
Financial support:
Authors’ declaration of personal interests:
- GMCM, VV, ES, GM, RS and GT do not have any conflict of interest.
Masclee et al. Page 9
Aliment Pharmacol Ther. Author manuscript; available in PMC 2013 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
- MM has received grants from the SAEC consortium (collaboration of academia and industry), and from
AstraZeneca, Pfizer. MM’s work on drug safety is supported by the National Institute for Health Research (NIHR)
Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
- JG has received research and/or educational funding, consulting fees, contract payments and speaker’s honoraria
from AstraZeneca, Horizon, Logical Therapeutics, Pfizer and POZEN. He has received consulting fees from
Boehringer Ingelheim.
- SHD has consulted for AstraZeneca, Novartis, and GSK. The Pharmaco-epidemiology Program at the Harvard
School of Public Health has been partially supported by training grants from Pfizer, Novartis and Asia.
- EJK has served as speaker and advisory board member for AstraZeneca.
- MS is head of an academic unit that conducts some research for pharmaceutical companies: Pfizer, Lilly,
AstraZeneca, Boehringer Ingelheim. All research is done under the condition of publication freedom.
Acknowledgments
Declaration of funding interests: This study has been funded by AstraZeneca PLC under contractual conditions
with Erasmus University that ensure freedom of publication. The study was designed and conducted independently
from AstraZeneca.
Abbreviations
ATC Anatomical Therapeutic Chemical
BNF British National Formulary
CI Confidence Interval
COX Cyclo-oxygenase
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Table 1
Baseline characteristics of cases with symptomatic UGI events (UGI bleeding and
symptomatic ulcer) and matched controls by database.
United Kingdom The Netherlands Italy
cases
N=307
controls
N=48,860
P-
value
cases
N=17
controls
N=374
P-
value
cases
N=74
controls
N=8,334 P-value
n(%) n(%) n(%) n(%) n(%) n(%)
Age in yrs (mean±sd) * 74.0 (10.9) 71.2 (9.5) NA 75.0 (9.6) 73.9 (9.7) NA 69.9 (10.4) 68.5 (9.4) NA
Age category: * NA NA NA
  50 – 64 60 (19.5) 12,222 (25.0) 2 (11.8) 63 (16.8) 26 (35,1) 3,385 (40.6)
  65 – 74 101 (32.9) 18,422 (37.7) 6 (35.3) 119 (31.8) 22 (29,7) 2,534 (30.4)
  ≥ 75 146 (47.6) 18,216 (37.3) 9 (52.9) 192 (51.3) 26 (35,1) 2,415 (29.0)
Gender (n(%) male) * 132 (43.0) 13,544 (27.7) NA 5 (29.4) 71 (19.0) NA 20 (27.0) 1,668 (20.0) NA
UGI risk factors:
  Age ≥ 65 yrs 247 (80.5) 36,638 (75.0) 0.243 15 (88.2) 311 (83.2) - 48 (64.9) 4,949 (59.4) 0.670
  Prior UGI event 57 (18.6) 2,634 (5.4) 0.028 1 (5.9) 4 (1.1) 0.694 2 (2.7) 101 (1.2) 0.282
  Use of antiplatelets 106 (34.5) 11,647 (23.8) 0.123 10 (58.8) 86 (23.0) 0.042 12 (16.2) 329 (3.9) 0.007
  Use of anticoagulants 14 (4.6) 676 (1.4) 0.032 1 (5.9) 14 (3.7) 0.912 0 (0) 36 (0.4) -
  Use of glucocorticoids 18 (5.9) 1,298 (2.7) 0.289 0 (0) 11 (2.9) - 3 (4.1) 98 (1.2) 0.143
Number of UGI risk factors: * NA NA NA
  0 36 (11.7) 10,578 (21.6) 2 (11.8) 61 (16.3) 24 (32.4) 3,300 (39.6)
  1 131 (42.7) 24,332 (49.8) 4 (23.5) 205 (54.8) 35 (47.3) 4,567 (54.8)
  2 112 (36.5) 13,310 (27.2) 10 (58.8) 103 (27.5) 15 (20.3) 455 (5.5)
  3 25 (8.1) 619 (1.3) 1 (5.9) 5 (1.3) 0 (0) 12 (0.1)
  4 3 (1) 21 (0)
Other comorbidities:
  Dyspepsia 14 (4.6) 1,613 (3.3) 0.222 1 (5.9) 16 (4.3) 0.555 2 (2.7) 296 (3.6) 0.770
  Smoking 252 (82.1) 39,153 (80.1) 0.272 4 (23.5) 54 (14.4) 0.599 3 (4.1) 278 (3.3) 0.714
  Heart Failure 31 (10.1) 2,101 (4.3) 0.158 0 (0) 34 (9.1) - 1 (1.4) 138 (1.7) 0.487
  Diabetes mellitus 63 (20.5) 6,542 (13.4) 0.062 2 (11.8) 62 (16.6) 0.525 13 (17.6) 878 (10.5) 0.151
Concomitant use of other medication:
  SSRIs 34 (11.1) 3,071 (6.3) <0.001 0 (0) 14 (3.7) - 1 (1.4) 29 (0.3) 0.341
  Spironolactone 5 (1.6) 391 (0.8) 0.423 0 (0) 6 (1.6) - (0) (0) -
  calcium channel blockers 68 (22.1) 7,619 (15.6) 0.097 0 (0) 45 (12.0) - (0) (0) 0.646
Duration of episode#:
 < 1 month 151 (49.2) 25,888 (53.0) 0.150 6 (35.3) 254 (67.9) 0.046 66 (89.2) 7,111 (85.3) 0.329
  1-6 months 106 (34.5) 13,921 (28.5) 0.036 8 (47.1) 95 (25.4) 0.025 7 (9.5) 1,151 (13.8) 0.440
  6-12 months 24 (7.8) 4,095 (8.4) 0.859 1 (5.9) 14 (3.7) 0.306 0 (0) 48 (0.6) -
 < 12 months 26 (8.5) 4,956 (10.1) 0.842 2 (11.8) 11 (2.9) 0.025 1 (1.4) 24 (0.3) 0.098
*
Matching variables: age, gender and number of individual UGI risk factors.
SSRIs, selective serotonin reuptake inhibitors.
NA, Not applicable; matching criteria.
#
Episodes of NSAID use were defined as consecutive NSAID prescriptions with intervening gaps not exceeding the duration of the previous
NSAID prescription. The duration of an NSAID episode was calculated by dividing the prescribed quantity by daily dose regimen (United
Kingdom/Netherlands) or the indication-specific defined daily dose (Italy). The end of an NSAID episode was defined as the end of the duration of
the last NSAID prescription within that episode or the end of follow-up, whichever was earliest.
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Table 2
The risk of symptomatic UGI events and UGI bleeding in users of nsNSAID+GPA (≥80%
adherence) as compared to coxib users.
Symptomatic UGI events (UGI bleeding and symptomatic ulcer) UGI bleeding
Cases Controls ORmatch
ed
(95%CI)
P-
value ORadj†(95%CI)
P-
value
Cases Controls ORmatche
d (95%CI)
P-value ORadj†
(95%CI)
P-value
n (%) n (%) n (%) n (%)
United
Kingdom
Coxib 128
(41.7)
24,722
(50.6)
1.00 1.00 86 (44.3) 14,835
(51.1)
1.00 1.00
nsNSAID+GPA# 179(58.3)
24,138
(49.4)
1.02
(0.77-
1.36)
0.883 1.05 (0.77-
1.45)
0.742 108
(55.7)
14,222
(48.9)
0.90 (0.63-
1.29)
0.568 1.20 (0.80-
1.80)
0.375
The
Netherlands *
Coxib 13 (76.5) 243 (65.0) 1.00 1.00 10 (71.4) 172 (60.4) 1.00 1.00
nsNSAID+GPA# 4 (23.5) 131 (35.0) 0.44(0.13-
1.48)
0.183 0.54 (0.16-
1.84)
0.323 4 (28.6) 113 (39.6) 0.53 (0.15-
1.88)
0.326 0.63 (0.18-
2.24)
0.478
Italy Coxib 44 (59.5) 6,201 (74.4) 1.00 1.00 6 (35.3) 1,124 (64.6) 1.00 1.00
nsNSAID+GPA# 30 (40.5) 2,133 (25.6) 1.22(0.69-
2.17)
0.500 0.79 (0.27-
2.35)
0.673 11 (64.7) 616 (35.4) 2.85 (0.92-
8.80)
0.069 0.59 (0.05-
6.55)
0.669
Pooled on
patient level
Coxib 185
(46.5)
31,166
(54.1)
1.00 1.00 102
(45.3)
16,131
(51.9)
1.00 1.00
nsNSAID+GPA# 213(53.5)
26,402
(45.9)
1.01
(0.79-
1.30)
0.918 1.02 (0.77-
1.37)
0.880 123
(54.7)
14,951
(48.1)
0.96 (0.69-
1.33)
0.800 1.14 (0.78-
1.65)
0.503
Cases and controls are matched on age, gender and number of individual UGI risk factors.
*
For NL: adjusted model also includes use of antiplatelets.
†Adjusted for dose of NSAID, length of NSAID episode and density of NSAID use within episode. Only subjects included with known dosage of
NSAID (UK 80.2%; NL 100%; IT 35.3%).
#
nsNSAID+GPA (≥80% adherence)
Aliment Pharmacol Ther. Author manuscript; available in PMC 2013 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Masclee et al. Page 17
Table 3
Risk factors for symptomatic UGI events (UGI bleeding and symptomatic ulcer) and UGI
bleeding; stratified analyses on data pooled on patient level.
Symptomatic UGI events (UGI bleeding and
symptomatic ulcer) UGI bleeding
Cases
n (%)
ORmatched*
(95% CI) P-value
P-value
Interaction
terms
Cases
n (%)
ORmatched*
(95% CI) P-value
P-value
Interaction
terms
Individual UGI risk
factors:
Age < 65 yrs Coxib 34 (38.6) 1.00 11 (31.4) 1.00
nsNSAID+GPA# 54 (61.4) 1.01 (0.79-1.30) 0.918 0.055 24 (68.6) 1.61 (0.67-3.87) 0.291 0.466
Age ≥ 65 yrs Coxib 151 (48.7) 1.00 91 (47.9) 1.00
nsNSAID+GPA# 159 (51.3) 0.88 (0.67-1.17) 0.394 99 (52.1) 0.88 (0.62-1.26) 0.488
No prior UGI event Coxib 171 (50.6) 1.00 93 (50.0) 1.00
nsNSAID+GPA# 167 (49.4) 0.98 (0.75-1.28) 0.877 0.152 93 (50.0) 0.86 (0.60-1.23) 0.397 0.417
Prior UGI event Coxib 14 (23.3) 1.00 9 (23.1) 1.00
nsNSAID+GPA# 46 (76.7) 1.73 (0.81-3.70) 0.159 30 (76.9) 1.90 (0.74-4.86) 0.182
No use of antiplatelets Coxib 120 (44.4) 1.00 59 (41.0) 1.00
nsNSAID+GPA# 150 (55.6) 1.23 (0.91-1.66) 0.181 <0.001 85 (59.0) 1.24 (0.83-1.87) 0.298 0.008
Use of antiplatelets Coxib 65 (50.8) 1.00 43 (53.1) 1.00
nsNSAID+GPA# 63 (49.2) 0.69 (0.44-1.08) 0.108 38 (46.9) 0.62 (0.34-1.06) 0.079
No use of
anticoagulants Coxib 182 (47.5) 1.00 99 (46.7) 1.00
nsNSAID+GPA# 201 (52.5) 0.99 (0.76-1.27) 0.904 0.078 113 (53.3) 0.91 (0.65-1.28) 0.603 0.085
Use of
anticoagulants Coxib 3 (20.0) - 3 (23.1) -
nsNSAID+GPA# 12 (80.0) 10 (76.9)
Symptomatic UGI events (UGI bleeding and
symptomatic ulcer) UGI bleeding
Individual UGI risk
factors:
Cases
n (%)
ORmatched*
(95% CI) P-value
P-value
Interaction
terms
Cases
n (%)
ORmatched*
(95% CI) P-value
P-value
Interaction
terms
No use of
glucocorticoids Coxib 180 (47.7) 1.00 99 (46.5) 1.00
nsNSAID+GPA# 197 (52.3) 0.96 (0.74-1.24) 0.740 0.280 114 (53.5) 0.91 (0.65-1.27) 0.571 0.724
Use of
glucocorticoids Coxib 5 (23.8) 1.00 3 (25.0) 1.00
nsNSAID+GPA# 16 (76.2)
7.03 (1.35-
36.45) 0.020 9 (75.0)
4.15 (0.72-
24.01) 0.112
Use of
glucocorticoids ## nsNSAID+GPA# 16 (76.2)
9.01 (1.61-
50.50) 0.012 9 (75.0)
4.81 (0.79-
29.20) 0.088
Before rofecoxib
withdrawal † Coxib 162 (62.5) 1.00 91 (64.1) 1.00
nsNSAID+GPA# 97 (37.5) 1.05 (0.79-1.40) 0.729 0.702 51 (35.9) 0.92 (0.62-1.34) 0.649 0.781
After rofecoxib
withdrawal ‡ Coxib 23 (16.5) 1.00 11 (13.3) 1.00
nsNSAID+GPA# 116 (83.5) 0.91 (0.57-1.47) 0.702 72 (86.7) 1.10 (0.56-2.15) 0.781
*
Matched on age, gender and number of individual UGI risk factors.
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#
nsNSAID+GPA (≥80% adherence).
##Adjusted for equipotent dosage of prednisone (low dosage: 5 to 10 mg/day; moderate dosage: 10 to 20 mg/day; high-dosage: >20 mg/day)
†
Rofecoxib withdrawal in September 2004, analysis until 2005.
‡Analysis from 2005 and subsequent years.
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